Small studies suggest liraglutide and semaglutide may reduce binge eating frequency, but robust long-term evidence is lacking and no GLP-1 drug is licensed for this indication
Unlimited answers to questions, anytime, 100% online
Published clinical guidelines from organizations including the American Society of Metabolic and Bariatric Surgery and the Obesity Medicine Association have identified GLP-1 receptor agonists as appropriate pharmacological interventions in patients with a BMI of 30 or above (classified as obesity), or BMI of 27 or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea - the same criteria framework used by the FDA in evaluating GLP-1 medications for their obesity management indications
Prior to making any investment decision, it is recommended that readers consult directly with Lexaria Bioscience and seek advice from a qualified investment advisor.
(2020, February 21)
Despite these associations, catestatin has received limited attention as a therapeutic candidate, in part because it does not conform neatly to classical endocrine paradigms and lacks a single dominant receptor target
:max_bytes(150000):strip_icc()/VWH-GettyImages-2277072224-253694d5d5264cc6b2ba7d55e3d92845.jpg)
